China 
Africa 
Explore chapters and articles related to this topic
Nutraceutical Components in the Treatment of Psoriasis and Psoriatic Arthritis
Published in Siba P. Raychaudhuri, Smriti K. Raychaudhuri, Debasis Bagchi, Psoriasis and Psoriatic Arthritis, 2017
Urmila Jarouliya, Raj K. Keservani
Traditional therapy for psoriasis is based on the severity of the disease. Mild and limited psoriasis treatment includes topical corticosteroids, tars, anthralin, calcipotriene (a vitamin D3 analog), tazarotene (a retinoid), and phototherapy. A topical combination of calcipotriene and betamethasone (Taclonex®) has shown greater efficacy in severe psoriasis than monotherapy with either alone (Kaufmann et al., 2002).
Fixed-Dose Corticosteroid and Calcipotriene Combination Therapy
Published in John Y. M. Koo, Ethan C. Levin, Argentina Leon, Jashin J. Wu, Mark G. Lebwohl, Mild to Moderate Psoriasis, 2014
Ethan C. Levin, John Y. M. Koo
Fixed-dose calcipotriene 0.005% and betamethasone dipropionate 0.064% (Taclonex®) is approved by the U.S. Food and Drug Administration (FDA) for the treatment of plaque psoriasis in adults ≥18 years old in both ointment and suspension formulations (known as “gel” outside of the United States). The ointment formulation has been available in the United States since January 2006 [10] for once-daily application up to four weeks. The suspension formulation was first approved for scalp psoriasis in 2006 and the indication was expanded to include other parts of the body in October 2012 [11] for once-daily application up to eight weeks. As per label, the maximum recommended weekly dose of both the ointment and suspension is 100 g. Outside of the United States, the ointment formulation is called Dovobet® or Daivobet®, and the suspension formulation may be referred to as gel or Xiamiol®.
Topical Agents
Published in John Y. M. Koo, Ethan C. Levin, Argentina Leon, Jashin J. Wu, Alice B. Gottlieb, Moderate to Severe Psoriasis, 2014
Rosemary deShazo, Gerald G. Krueger, Kristina Callis Duffin
Vitamin D Analog—Corticosteroid Combination Preparations Numerous strategies have been employed to take advantage of the rapid onset and efficacy of potent topical corticosteroids and the safety of vitamin D analogs. Some dermatologists have advocated mixing or simultaneously applying calcipotriene and superpotent corticosteroids. However, formulations of these agents may not be compatible when applied together or mixed in this fashion [64]. The availability of a stable two-compound ointment has obviated the need for applying two separate agents. The two-compound ointment (in the United States, Taclonex®, and in Europe and Canada, Dovobet®) contains calcipotriene 0.005% (equivalent to calcipotriene 50µg/g) and betamethasone dipropionate 0.064% (equivalent to betamethasone 0.5 mg/g) [72] and is indicated for the treatment of psoriasis in adults for up to four weeks of continuous therapy. Taclonex® is also available as a gel for hair-bearing areas. Douglas et al. showed that the two-compound ointment used twice daily for four weeks was associated with a mean reduction of PASI from a baseline of 74.4%, which was significantly better than betamethasone dipropionate ointment twice daily (mean PASI reduction 61.3%) and calcipotriene ointment alone twice daily for four weeks (mean changes from baseline PASI of 55.3%). Papp et al. had similar results [73]. Studies of daily application of the two-compound ointment produced a mean PASI reduction of 69%–71% over four weeks [74,75] and a mean PASI reduction of 73.1% with daily use over eight weeks [76]. Once daily application has also been associated with greater compliance than twice daily application in two studies [77,78]. These studies suggest that the two-compound ointment, applied daily or b.i.d., has superior efficacy compared to betamethasone dipropionate or calcipotriene monotherapy. However, a head-to-head study of clobetasol propionate spray and once daily two-compound ointment revealed that 74% of clobetasol spray-treated patients obtained clear or almost clear, whereas only 47% of patients applying the two-compound ointment achieved clear/almost clear [79]. Although the two-compound ointment may not be as efficacious as b.i.d. superpotent clobetasol, once daily therapy for many patients may be a more desirable regimen.
Topical calcipotriol plus betamethasone dipropionate for the treatment of plaque psoriasis: a drug evaluation
Published in Expert Opinion on Pharmacotherapy, 2021
Caitlin G. Purvis, Esther A. Balogh, Courtney E. Heron, Steven R. Feldman
Combination calcipotriol/BD has a low systemic absorption and local anti-inflammatory and immunoregulatory effects [3]. When combined, calcipotriol mitigates both the atrophy and decreased epidermal barrier integrity caused by corticosteroids, while corticosteroids minimize the irritative effects of calcipotriol [1,10,31]. There are five topical formulations: ointment (Taclonex®), foam (Enstilar®), gel (Daivobet®), suspension (Taclonex®), and the newest vehicle approved in 2020, a cream (Wynzora®) [30,32–35] (Table 2). The maximum recommended dose for adults is 15 g/day and 100 g/week for the cream, ointment, gel, and suspension or 60 g every four days for the foam [12].